Insider Transactions in Q1 2024 at Madrigal Pharmaceuticals, Inc. (MDGL)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2024
|
Carole Huntsman Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,639
+24.08%
|
-
|
|
Jan 23
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
1,419
+17.84%
|
-
|
|
Jan 23
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
5,786
+21.77%
|
-
|
|
Jan 23
2024
|
Alex G. Howarth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,803
+20.4%
|
-
|
|
Jan 23
2024
|
William John Sibold President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
12,250
+16.44%
|
-
|
|
Jan 23
2024
|
Brian Joseph Lynch SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,639
+17.06%
|
-
|
|
Jan 16
2024
|
Brian Joseph Lynch SVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
949
-6.33%
|
$230,607
$243.92 P/Share
|
|
Jan 16
2024
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
550
-9.71%
|
$133,650
$243.92 P/Share
|
|
Jan 16
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,546
-9.34%
|
$375,678
$243.92 P/Share
|
|
Jan 16
2024
|
Alex G. Howarth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,067
-7.11%
|
$259,281
$243.92 P/Share
|